Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1α

Carcinogenesis

Volumn 32, Issue 12, 2011, Pages 1881-1889

  Wang, Hong ^a   Bian, Shengjie ^a   Yang, Chung S ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIGALLOCATECHIN GALLATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA; MICRORNA 210; PROLINE; UNCLASSIFIED DRUG;

AMINOHYDROXYLATION; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ANCHORAGE; CELL HYPOXIA; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG PROTEIN BINDING; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN TARGETING; TEA; UBIQUITINATION; UPREGULATION;

ANIMALS; BLOTTING, WESTERN; CATECHIN; CELL DIVISION; CELL LINE, TUMOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOPRECIPITATION; LUNG NEOPLASMS; MICE; MICRORNAS; TEA; UP-REGULATION;

EID: 81855206547     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr218     Document Type: Article

References (50)

1. Khan, N. et al. (2006) Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res., 66, 2500-2505.
2. Yang, C.S. et al. (2009) Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat. Rev. Cancer, 9, 429-439.
3. Liang, G. et al. (2010) Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. Int. J. Oncol., 37, 111-123.
4. Shimizu, M. et al. (2010) (-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells. Chem. Biol. Interact., 185, 247-252.
5. Zhang, Q. et al. (2006) Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol. Cancer Ther., 5, 1227-1238.
6. Domingo, D.S. et al. (2010) Anti-angiogenic effects of epigallocatechin-3-gallate in human skin. Int. J. Clin. Exp. Pathol., 3, 705-709.
7. Thomas, R. et al. (2005) Epigallocatechin gallate inhibits HIF-1alpha degradation in prostate cancer cells. Biochem. Biophys. Res. Commun., 334, 543-548.
8. Weinreb, O. et al. (2007) A novel approach of proteomics and transcriptomics to study the mechanism of action of the antioxidant-iron chelator green tea polyphenol (-)-epigallocatechin-3-gallate. Free Radic. Biol. Med., 43, 546-556.
9. Zhou, Y.D. et al. (2004) Hypoxia-inducible factor-1 activation by (-)-epicatechin gallate: potential adverse effects of cancer chemoprevention with high-dose green tea extracts. J. Nat. Prod., 67, 2063-2069.
10. Kaelin, W.G.Jr. et al. (2008) Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell, 30, 393-402.
11. Poon, E. et al. (2009) Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev. Mol. Med., 11, e26.
12. Semenza, G.L. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 3, 721-732.
13. Kaelin, W.G. Jr (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat. Rev. Cancer, 8, 865-873.
14. Bruick, R.K. (2003) Oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor. Genes Dev., 17, 2614-2623.
15. Bruick, R.K. et al. (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science, 294, 1337-1340.
16. Epstein, A.C. et al. (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 107, 43-54.
17. Bartel, D.P. (2009) MicroRNAs: target recognition and regulatory functions. Cell, 136, 215-233.
18. Friedman, R.C. et al. (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res., 19, 92-105.
19. Du, T. et al. (2005) microPrimer: the biogenesis and function of microRNA. Development, 132, 4645-4652.
20. Bartel, D.P. (2004) MicroRNAs. genomics, biogenesis, mechanism, and function. Cell, 116, 281-297.
21. Liu, J. et al. (2004) Argonaute2 is the catalytic engine of mammalian RNAi. Science, 305, 1437-1441.
22. Guo, H. et al. (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature, 466, 835-840.
23. Kosik, K.S. (2010) MicroRNAs and cellular phenotypy. Cell, 143, 21-26.
24. Lu, Y. et al. (2007) Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev. Biol., 310, 442-453.
25. Liu, X. et al. (2009) Uncovering growth-suppressive microRNAs in lung cancer. Clin. Cancer Res., 15, 1177-1183.
26. Lu, J. et al. (2005) MicroRNA expression profiles classify human cancers. Nature, 435, 834-838.
27. Harris, K.S. et al. (2006) Dicer function is essential for lung epithelium morphogenesis. Proc. Natl Acad. Sci. USA, 103, 2208-2213.
28. Kumar, M.S. et al. (2009) Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev., 23, 2700-2704.
29. Li, G.X. et al. (2010) Pro-oxidative activities and dose-response relationship of (-)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro. Carcinogenesis, 31, 902-910.
30. Hou, Z. et al. (2005) Mechanism of action of (-)-epigallocatechin-3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. Cancer Res., 65, 8049-8056.
31. Pear, W.S. et al. (1993) Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl Acad. Sci. USA, 90, 8392-8396.
32. Bernardi, R. et al. (2006) PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature, 442, 779-785.
33. Kondo, K. et al. (2002) Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell, 1, 237-246.
34. Yan, Q. et al. (2007) The hypoxia-inducible factor 2alpha N-terminal and Cterminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol. Cell. Biol., 27, 2092-2102.
35. Huang, X. et al. (2009) Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol. Cell, 35, 856-867.
36. Wang, H. et al. (2004) Positive and negative modulation of the transcriptional activity of the ETS factor ESE-1 through interaction with p300, CREB-binding protein, and Ku 70/86. J. Biol. Chem., 279, 25241-25250.
37. Wang, H. et al. (2010) RhoH plays distinct roles in T-cell migrations induced by different doses of SDF1 alpha. Cell Signal., 22, 1022-1032.
38. Shim, J.H. et al. (2008) (-)-Epigallocatechin gallate regulates CD3-mediated T cell receptor signaling in leukemia through the inhibition of ZAP-70 kinase. J. Biol. Chem., 283, 28370-28379.
39. Tsuchiya, S. et al. (2010) MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J. Biol. Chem., 2010, 2.
40. Lu, G. et al. (2008) Synergistic inhibition of lung tumorigenesis by a combination of green tea polyphenols and atorvastatin. Clin. Cancer Res., 14, 4981-4988.
41. Murray, N.J. et al. (1994) Study of the interaction between salivary prolinerich proteins and a polyphenol by 1H-NMR spectroscopy. Eur. J. Biochem., 219, 923-935.
42. Baxter, N.J. et al. (1997) Multiple interactions between polyphenols and a salivary proline-rich protein repeat result in complexation and precipitation. Biochemistry, 36, 5566-5577.
43. Canon, F. et al. (2010) Ability of a salivary intrinsically unstructured protein to bind different tannin targets revealed by mass spectrometry. Anal. Bioanal. Chem., 398, 815-822.
44. Chung, J.Y. et al. (2001) Mechanisms of inhibition of the Ras-MAP kinase signaling pathway in 30.7b Ras 12 cells by tea polyphenols (-)-epigallocatechin-3-gallate and theaflavin-3, 3'-digallate. FASEB J., 15, 2022-2024.
45. Croce, C.M. (2009) Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet., 10, 704-714.
46. Goda, N. et al. (2003) Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol. Cell. Biol., 23, 359-369.
47. Mazumdar, J. et al. (2010) HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc. Natl Acad. Sci. USA, 107, 14182-14187.
48. Sumiyoshi, Y. et al. (2006) Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin. Cancer Res., 12, 5112-5117.
49. Koshiji, M. et al. (2004) HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J., 23, 1949-1956.
50. Dang, C.V. et al. (2008) The interplay between MYC and HIF in cancer. Nat. Rev. Cancer, 8, 51-56.